Antibody Drug Conjugates Market Size
The Global Antibody Drug Conjugates Market size reached USD 5,032.8 million in 2022 and is projected to witness lucrative growth by reaching up to USD 16,594.6 million by 2030. The market is exhibiting at a CAGR of 16.6% during the forecast period (2024-2031). The global antibody drug conjugates market is anticipated to rise throughout the forecast period due to the increasing prevalence of cancer and advancements in antibody engineering and conjugation technologies.
Antibody drug conjugates (ADCs) are on the brink of widespread use for the targeted treatment of cancer. ADCs manage the toxicity of drugs with narrow therapeutic windows by guiding highly toxic compounds to the target cells, sparing healthy cells.
For instance, YL201 is an antibody drug conjugate (ADC) composed of a monoclonal antibody against a tumor-associated antigen (TAA) linked to a cytotoxic agent with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of YL201 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an unknown mechanism of action.
The global antibody drug conjugates market is driven by factors such as the increasing prevalence of cancer, growing investments in research and developments related to cancer, increasing innovative and targeted treatment options for cancer, and advancements in antibody engineering and conjugation technologies.
Market Summary
| Metrics | Details |
| CAGR | 16.6% |
| Size Available for Years | 2021-2030 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (USD ) |
| Segments Covered | Application, Technology, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
To know more Insights - Download Sample
Market Dynamics
Increasing Prevalence Of Cancer
The rising incidence of cancer globally is a significant driver for the antibody drug conjugates market. As the number of cancer cases continues to grow, there is a growing need for more effective and targeted therapies, which ADCs can provide.
ADCs offer a personalized approach to cancer treatment by targeting specific antigens expressed on cancer cells. This targeted therapy approach allows for greater efficacy and reduced toxicity compared to traditional chemotherapy, making ADCs an attractive option for both patients and healthcare providers.
Advancements in Antibody Engineering And Conjugation Technologies
Advancements in antibody engineering and conjugation technologies are a major factor in improving the market opportunity of antibody drug conjugates. Significant progress has been made in antibody engineering and conjugation technologies, enabling the development of more potent and stable ADCs. These advancements have improved the specificity and efficacy of ADCs, driving their adoption in clinical practice.
Advances in genetic engineering have enabled the production of highly specific recombinant antibodies. These engineered antibodies have been constructed in the hunt for novel therapeutic drugs with enhanced immunoprotective abilities. Advanced antibody engineering techniques have extensive applications in immunology, biotechnology, diagnostics, and therapeutic medicines.
High Production Cost & Side Effects of ADCs
High production costs and side effects associated with ADCs hamper the market growth during the forecast period. The development of ADCs involves extensive research, preclinical studies, clinical trials, and regulatory processes, which can be costly and time-consuming. The high development costs pose a significant barrier, particularly for smaller biotechnology companies or academic institutions with limited resources, hindering the advancements of ADCs.
There are mild to moderate side effects associated with the antibody-drug conjugates such as a manageable side-effect profile, with nausea and vomiting being the most common toxicities. Other adverse effects include fever, infection, vomiting, and stomatitis. Serious adverse effects include low blood counts, liver damage, IRRs, and bleeding.
Market Segment Analysis
The global antibody drug conjugates market is segmented based on application, technology, and region.
Based On Application, The Breast Cancer Segment Dominates The Market Share
Based on application, the breast cancer segment dominates the market share of around 48.6% during the forecast period. Breast cancer is mostly seen in middle-aged and older women, with a median age of 62. Half of those diagnosed are 62 or younger, and a small number are younger than 45. Women with certain gene mutations, such as BRCA1 or BRCA2, have an increased risk of breast cancer.
For instance, in January 2023, Sun Pharmaceutical Industries Limited announced that one of its wholly-owned subsidiaries has launched Palbociclib, a novel anti-cancer drug, in India for patients who have advanced breast cancer, the drug is available under the brand name PALENO.
Source: DataM Intelligence Analysis (2023)
Market Geographical Share
North America Holds The Largest Market Share Due To Active New Drug Pipeline Projects And New Product Launches
North America holds the largest market share of about 51.4% during the forecast period due to the active new drug pipeline projects and new product launches. There are a total of 264 antibody-drug conjugates (ADCs) in pharma’s pipeline, 161 of which are being developed in North America, making it the continent with the highest number of ADCs in development. Moreover, due to the increasing cases of cancer patients will keep the requirement for antibody drug conjugates.
Source: DataM Intelligence Analysis (2023)
Antibody Drug Conjugates Companies
The major global players include Takeda Pharmaceutical Company Ltd., Hoffmann-La Roche Ltd., Pfizer Inc., AstraZeneca, Gilead Sciences Inc., Seagen Inc., Astellas Pharma, Daiichi Sankyo Company Ltd., GlaxoSmithKline Plc, and ADC Therapeutics.
COVID-19 Impact on Market
The Covid-19 pandemic has had a negative impact on the global antibody drug conjugates market, with declined patient visits and reduced diagnosis rates due to strict lockdown restrictions. Additionally, a prolonged halt in research and development (R&D) activities affected the market’s development during the critical period.
The trade market was disturbed during the period, and the supply chain of GMP raw materials required in the manufacturing process was disturbed. The pandemic has caused people to choose advanced healthcare measures, which will result in an increased number of cancer diagnoses and, subsequently, the requirement for antibody drug conjugates.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war significantly impacted the antibody drug conjugates market growth. Significant contributions are made by Ukraine and Russia to international cancer clinical trials. The situation in Ukraine will have a variety of effects on performing clinical trials, but it mainly affects the closure of treatment facilities, internal displacement, and forced migration.
The war is expected to have an effect on the contribution of Russian clinical trial sites. Because resources and manpower are not allocated according to priority, cancer care in these nations has worsened. Companies like Pfizer, Bayer, Sanofi, and a few others have delayed making significant investments or developments in the country leading to a significant impact on antibody drug conjugates market.
Key Developments
- In May 2023, Sony Corporation, a technology company and Astellas Pharma Inc., a pharmaceutical company, announced that they entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate (ADC) platform in oncology based on Sony's unique polymeric material, KIRAVIA ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells.
- In May 2023, Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported its financial results for the first quarter of 2023, its recent business highlights, and a preview of select anticipated milestones.
- In January 2023, Bridge Biotherapeutics, a biotechnology company and Pinotbio, a biotechnology company, signed a memorandum of understanding (MoU) to develop new therapeutic cancer candidates using antibody drug conjugates platform technology. Bridge Biotherapeutics will provide private anticancer targets, while Pinotbio will provide linkers and drugs.
Why Purchase the Report?
- To visualize the global antibody drug conjugates market segmentation based on application, technology, and region and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of antibody drug conjugates market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global antibody drug conjugates market report would provide approximately 54 tables, 46 figures, and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
